Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 7/2016

01-07-2016 | Review

The management of osteoporosis in children

Authors: L. M. Ward, V. N. Konji, J. Ma

Published in: Osteoporosis International | Issue 7/2016

Login to get access

Summary

This article reviews the manifestations and risk factors associated with osteoporosis in childhood, the definition of osteoporosis and recommendations for monitoring and prevention. As well, this article discusses when a child should be considered a candidate for osteoporosis therapy, which agents should be prescribed, duration of therapy and side effects.

Abstract

There has been significant progress in our understanding of risk factors and the natural history of osteoporosis in children over the past number of years. This knowledge has fostered the development of logical approaches to the diagnosis, monitoring, and optimal timing of osteoporosis intervention in this setting. Current management strategies are predicated upon monitoring at-risk children to identify and then treat earlier rather than later signs of osteoporosis in those with limited potential for spontaneous recovery. On the other hand, trials addressing the prevention of the first-ever fracture are still needed for children who have both a high likelihood of developing fractures and less potential for recovery. This review focuses on the evidence that shapes the current approach to diagnosis, monitoring, and treatment of osteoporosis in childhood, with emphasis on the key pediatric-specific biological principles that are pivotal to the overall approach and on the main questions with which clinicians struggle on a daily basis. The scope of this article is to review the manifestations of and risk factors for primary and secondary osteoporosis in children, to discuss the definition of pediatric osteoporosis, and to summarize recommendations for monitoring and prevention of bone fragility. As well, this article reviews when a child is a candidate for osteoporosis therapy, which agents and doses should be prescribed, the duration of therapy, how the response to therapy is adjudicated, and the short- and long-term side effects. With this information, the bone health clinician will be poised to diagnose osteoporosis in children and to identify when children need osteoporosis therapy and the clinical outcomes that gauge efficacy and safety of treatment.
Literature
1.
Bachrach LK (2014) Diagnosis and treatment of pediatric osteoporosis. Curr Opin Endocrinol Diabetes Obes 21:454–460PubMedCrossRef
2.
Makitie O (2013) Causes, mechanisms and management of paediatric osteoporosis. Nat Rev Rheumatol 9:465–475PubMedCrossRef
3.
Saraff V, Schneider J, Colleselli V, Ruepp M, Rauchenzauner M, Neururer S, Geiger R, Hogler W (2015) Sex-, age-, and height-specific reference curves for the 6-min walk test in healthy children and adolescents. Eur J Pediatr 174(6):837–840PubMedCrossRef
4.
Bianchi ML, Leonard MB, Bechtold S, Hogler W, Mughal MZ, Schonau E, Sylvester FA, Vogiatzi M, van den Heuvel-Eibrink MM, Ward L (2014) Bone health in children and adolescents with chronic diseases that may affect the skeleton: the 2013 ISCD Pediatric Official Positions. J Clin Densitom 17:281–294PubMedCrossRef
5.
6.
Ben Amor IM, Roughley P, Glorieux FH, Rauch F (2013) Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. J Bone Miner Res 28:2001–2007PubMedCrossRef
7.
Marini JC, Reich A, Smith SM (2014) Osteogenesis imperfecta due to mutations in non-collagenous genes: lessons in the biology of bone formation. Curr Opin Pediatr 26:500–507PubMedPubMedCentralCrossRef
8.
Rauch F, Lalic L, Roughley P, Glorieux FH (2010) Genotype-phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I. Eur J Hum Genet 18:642–647PubMedPubMedCentralCrossRef
9.
10.
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77–93PubMedCrossRef
11.
Cummings EA, Ma J, Fernandez CV, Halton J, Alos N, Miettunen PM, Jaremko JL, Ho J, Shenouda N, Matzinger MA, Lentle B, Stephure D, Stein R, Sbrocchi AM, Rodd C, Lang B, Israels S, Grant RM, Couch R, Barr R, Hay J, Rauch F, Siminoski K, Ward LM (2015) Incident vertebral fractures in children with leukemia during the four years following diagnosis. J Clin Endocrinol Metab 100:3408–3417PubMedPubMedCentralCrossRef
12.
LeBlanc CM, Ma J, Taljaard M, Roth J, Scuccimarri R, Miettunen P, Lang B, Huber AM, Houghton K, Jaremko JL, Ho J, Shenouda N, Matzinger MA, Lentle B, Stein R, Sbrocchi AM, Oen K, Rodd C, Jurencak R, Cummings EA, Couch R, Cabral DA, Atkinson S, Alos N, Rauch F, Siminoski K, Ward LM (2015) Incident vertebral fractures and risk factors in the first three years following glucocorticoid initiation among pediatric patients with rheumatic disorders. J Bone Miner Res 30:1667–1675PubMedPubMedCentralCrossRef
13.
McMillan HJ, Campbell C, Mah JK (2010) Duchenne muscular dystrophy: Canadian paediatric neuromuscular physicians survey. Can J Neurol Sci 37:195–205PubMedCrossRef
14.
Hyams JS (2014) Biologics in pediatric Crohn’s disease: is it time to move to an earlier therapeutic approach? Expert Rev Clin Immunol 10:1423–1426PubMedCrossRef
15.
Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, Olson A, Johanns J, Marano CW, Heuschkel RB, Veereman-Wauters G, Griffiths AM, Baldassano RN (2008) Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn’s disease: results of the REACH study. Clin Gastroenterol Hepatol 6:1378–1384PubMedCrossRef
16.
Kessler EA, Becker ML (2014) Therapeutic advancements in juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 28:293–313PubMedCrossRef
17.
Billiau AD, Loop M, Le PQ, Berthet F, Philippet P, Kasran A, Wouters CH (2010) Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford) 49:1550–1558CrossRef
18.
Simonini G, Giani T, Stagi S, de Martino M, Falcini F (2005) Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford) 44:777–780CrossRef
19.
Griffin LM, Thayu M, Baldassano RN, DeBoer MD, Zemel BS, Denburg MR, Denson LA, Shults J, Herskovitz R, Long J, Leonard MB (2015) Improvements in bone density and structure during anti-TNF-alpha therapy in pediatric Crohn’s disease. J Clin Endocrinol Metab 100:2630–2639PubMedPubMedCentralCrossRef
20.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328PubMedCrossRef
21.
King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, Mendell JR, Kissel JT (2007) Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68:1607–1613PubMedCrossRef
22.
Halton J, Gaboury I, Grant R, Alos N, Cummings EA, Matzinger M, Shenouda N, Lentle B, Abish S, Atkinson S, Cairney E, Dix D, Israels S, Stephure D, Wilson B, Hay J, Moher D, Rauch F, Siminoski K, Ward LM, Canadian STOPP Consortium (2009) Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. J Bone Miner Res 24:1326–1334PubMedPubMedCentralCrossRef
23.
Feber J, Gaboury I, Ni A, Alos N, Arora S, Bell L, Blydt-Hansen T, Clarson C, Filler G, Hay J, Hebert D, Lentle B, Matzinger M, Midgley J, Moher D, Pinsk M, Rauch F, Rodd C, Shenouda N, Siminoski K, Ward LM (2012) Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome. Osteoporos Int 23:751–760PubMedCrossRef
24.
Huber AM, Gaboury I, Cabral DA, Lang B, Ni A, Stephure D, Taback S, Dent P, Ellsworth J, LeBlanc C, Saint-Cyr C, Scuccimarri R, Hay J, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM (2010) Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care Res (Hoboken) 62:516–526CrossRef
25.
Alos N, Grant RM, Ramsay T, Halton J, Cummings EA, Miettunen PM, Abish S, Atkinson S, Barr R, Cabral DA, Cairney E, Couch R, Dix DB, Fernandez CV, Hay J, Israels S, Laverdiere C, Lentle B, Lewis V, Matzinger M, Rodd C, Shenouda N, Stein R, Stephure D, Taback S, Wilson B, Williams K, Rauch F, Siminoski K, Ward LM (2012) High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. J Clin Oncol 30:2760–2767PubMedPubMedCentralCrossRef
26.
Phan V, Blydt-Hansen T, Feber J, Alos N, Arora S, Atkinson S, Bell L, Clarson C, Couch R, Cummings EA, Filler G, Grant RM, Grimmer J, Hebert D, Lentle B, Ma J, Matzinger M, Midgley J, Pinsk M, Rodd C, Shenouda N, Stein R, Stephure D, Taback S, Williams K, Rauch F, Siminoski K, Ward LM (2014) Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome. Osteoporos Int 25:627–637PubMedCrossRef
27.
Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral DA, Scuccimarri R, Miettunen PM, Roth J, Atkinson SA, Couch R, Cummings EA, Dent PB, Ellsworth J, Hay J, Houghton K, Jurencak R, Larche M, LeBlanc C, Oen K, Saint-Cyr C, Stein R, Stephure D, Taback S, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM (2012) Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care Res (Hoboken) 64:122–131CrossRef
28.
Kilpinen-Loisa P, Paasio T, Soiva M, Ritanen UM, Lautala P, Palmu P, Pihko H, Makitie O (2010) Low bone mass in patients with motor disability: prevalence and risk factors in 59 Finnish children. Dev Med Child Neurol 52:276–282PubMedCrossRef
29.
Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, Makitie O, Munns CF, Shaw N (2014) Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 pediatric official positions. J Clin Densitom 17:275–280PubMedCrossRef
30.
Hogler W, Wehl G, van Staa T, Meister B, Klein-Franke A, Kropshofer G (2007) Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database. Pediatr Blood Cancer 48:21–27PubMedCrossRef
31.
van Staa TP, Cooper C, Leufkens HG, Bishop N (2003) Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 18:913–918PubMedCrossRef
32.
Baty JM, Vogt EC (1935) Bone changes of leukemia in children. Am J Roentgenol 34:310–313
33.
Helenius I, Remes V, Salminen S, Valta H, Makitie O, Holmberg C, Palmu P, Tervahartiala P, Sarna S, Helenius M, Peltonen J, Jalanko H (2006) Incidence and predictors of fractures in children after solid organ transplantation: a 5-year prospective, population-based study. J Bone Miner Res 21:380–387PubMedCrossRef
34.
Valta H, Jalanko H, Holmberg C, Helenius I, Makitie O (2008) Impaired bone health in adolescents after liver transplantation. Am J Transplant 8:150–157PubMed
35.
Valta H, Makitie O, Ronnholm K, Jalanko H (2009) Bone health in children and adolescents after renal transplantation. J Bone Miner Res 24:1699–1708PubMedCrossRef
36.
Vautour LM, Melton LJ 3rd, Clarke BL, Achenbach SJ, Oberg AL, McCarthy JT (2004) Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int 15:160–167PubMedCrossRef
37.
Henderson RC, Berglund LM, May R, Zemel BS, Grossberg RI, Johnson J, Plotkin H, Stevenson RD, Szalay E, Wong B, Kecskemethy HH, Harcke HT (2010) The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy. J Bone Miner Res 25:520–526PubMedCrossRef
38.
Nelson DA, Kleerekoper M, Peterson EL (1994) Reversal of vertebral deformities in osteoporosis: measurement error or “rebound”? J Bone Miner Res 9:977–982PubMedCrossRef
39.
Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM (2012) The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int 23:2703–2711PubMedCrossRef
40.
Mostoufi-Moab S, Brodsky J, Isaacoff EJ, Tsampalieros A, Ginsberg JP, Zemel B, Shults J, Leonard MB (2012) Longitudinal assessment of bone density and structure in childhood survivors of acute lymphoblastic leukemia without cranial radiation. J Clin Endocrinol Metab 97:3584–3592PubMedPubMedCentralCrossRef
41.
Marinovic D, Dorgeret S, Lescoeur B, Alberti C, Noel M, Czernichow P, Sebag G, Vilmer E, Leger J (2005) Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study. Pediatrics 116:e102–e108PubMedCrossRef
42.
Gurney JG, Kaste SC, Liu W, Srivastava DK, Chemaitilly W, Ness KK, Lanctot JQ, Ojha RP, Nottage KA, Wilson CL, Li Z, Robison LL, Hudson MM (2014) Bone mineral density among long-term survivors of childhood acute lymphoblastic leukemia: results from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer 61:1270–1276PubMedPubMedCentralCrossRef
43.
Makitie O, Heikkinen R, Toiviainen-Salo S, Henriksson M, Puukko-Viertomies LR, Jahnukainen K (2013) Long-term skeletal consequences of childhood acute lymphoblastic leukemia in adult males: a cohort study. Eur J Endocrinol 168:281–288PubMedCrossRef
44.
Burger H, Van Daele PL, Grashuis K, Hofman A, Grobbee DE, Schutte HE, Birkenhager JC, Pols HA (1997) Vertebral deformities and functional impairment in men and women. J Bone Miner Res 12:152–157PubMedCrossRef
45.
Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793–800PubMedCrossRef
46.
Kerkeni S, Kolta S, Fechtenbaum J, Roux C (2009) Spinal deformity index (SDI) is a good predictor of incident vertebral fractures. Osteoporos Int 20:1547–1552PubMedCrossRef
47.
Kocks J, Ward K, Mughal Z, Moncayo R, Adams J, Hogler W (2010) Z-score comparability of bone mineral density reference databases for children. J Clin Endocrinol Metab 95:4652–4659PubMedCrossRef
48.
Leonard MB, Propert KJ, Zemel BS, Stallings VA, Feldman HI (1999) Discrepancies in pediatric bone mineral density reference data: potential for misdiagnosis of osteopenia. J Pediatr 135:182–188PubMedCrossRef
49.
Ma J, Siminoski K, Alos N, Halton J, Ho J, Lentle B, Matzinger M, Shenouda N, Atkinson S, Barr R, Cabral DA, Couch R, Cummings EA, Fernandez CV, Grant RM, Rodd C, Sbrocchi AM, Scharke M, Rauch F, Ward LM (2015) The choice of normative pediatric reference database changes spine bone mineral density Z-scores but not the relationship between bone mineral density and prevalent vertebral fractures. J Clin Endocrinol Metab 100:1018–1027PubMedCrossRef
50.
Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148PubMedCrossRef
51.
Grigoryan M, Guermazi A, Roemer FW, Delmas PD, Genant HK (2003) Recognizing and reporting osteoporotic vertebral fractures. Eur Spine J 12(Suppl 2):S104–S112PubMedPubMedCentralCrossRef
52.
Eastell R, Cedel SL, Wahner HW, Riggs BL, Melton LJ 3rd (1991) Classification of vertebral fractures. J Bone Miner Res 6:207–215PubMedCrossRef
53.
Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, Rauch F (2015) Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res 30(12):2150–2157PubMedCrossRef
54.
Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984–996PubMedCrossRef
55.
Siminoski K, Lentle B, Matzinger MA, Shenouda N, Ward LM (2014) Observer agreement in pediatric semiquantitative vertebral fracture diagnosis. Pediatr Radiol 44:457–466PubMedCrossRef
56.
Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, Brown J, Cowden EA, Goltzman D, Ioannidis G, Josse RG, Ste-Marie LG, Tenenhouse AM, Davison KS, Blocka KL, Pollock AP, Sibley J (2000) Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 29:228–251PubMedCrossRef
57.
Vallarta-Ast N, Krueger D, Wrase C, Agrawal S, Binkley N (2007) An evaluation of densitometric vertebral fracture assessment in men. Osteoporos Int 18:1405–1410PubMedCrossRef
58.
Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, Stephens D, Feldman BM (2000) Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 43:2402–2409PubMedCrossRef
59.
Siminoski K, Lee KC, Jen H, Warshawski R, Matzinger MA, Shenouda N, Charron M, Coblentz C, Dubois J, Kloiber R, Nadel H, O’Brien K, Reed M, Sparrow K, Webber C, Lentle B, Ward LM (2012) Anatomical distribution of vertebral fractures: comparison of pediatric and adult spines. Osteoporos Int 23:1999–2008PubMedCrossRef
60.
Buehring B, Krueger D, Checovich M, Gemar D, Vallarta-Ast N, Genant HK, Binkley N (2010) Vertebral fracture assessment: impact of instrument and reader. Osteoporos Int 21:487–494PubMedCrossRef
61.
Mayranpaa MK, Helenius I, Valta H, Mayranpaa MI, Toiviainen-Salo S, Makitie O (2007) Bone densitometry in the diagnosis of vertebral fractures in children: accuracy of vertebral fracture assessment. Bone 41:353–359PubMedCrossRef
62.
Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM (2000) Normative data for iliac bone histomorphometry in growing children. Bone 26:103–109PubMedCrossRef
63.
Bacchetta J, Wesseling-Perry K, Gilsanz V, Gales B, Pereira RC, Salusky IB (2013) Idiopathic juvenile osteoporosis: a cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography. Pediatr Rheumatol Online J 11:6PubMedPubMedCentralCrossRef
64.
65.
Crabtree NJ, Arabi A, Bachrach LK, Fewtrell M, El-Hajj Fuleihan G, Kecskemethy HH, Jaworski M, Gordon CM (2014) Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. J Clin Densitom 17:225–242PubMedCrossRef
66.
Zemel BS, Stallings VA, Leonard MB, Paulhamus DR, Kecskemethy HH, Harcke HT, Henderson RC (2009) Revised pediatric reference data for the lateral distal femur measured by Hologic Discovery/Delphi dual-energy X-ray absorptiometry. J Clin Densitom 12:207–218PubMedPubMedCentralCrossRef
67.
Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of the hand and wrist. Second edition. Stanford University Press, Stanford
68.
Kroger H, Kotaniemi A, Vainio P, Alhava E (1992) Bone densitometry of the spine and femur in children by dual-energy X-ray absorptiometry. Bone Miner 17:75–85PubMedCrossRef
69.
Zemel BS, Kalkwarf HJ, Gilsanz V, Lappe JM, Oberfield S, Shepherd JA, Frederick MM, Huang X, Lu M, Mahboubi S, Hangartner T, Winer KK (2011) Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab 96:3160–3169PubMedPubMedCentralCrossRef
70.
Crabtree NJ, Hogler W, Cooper MS, Shaw NJ (2013) Diagnostic evaluation of bone densitometric size adjustment techniques in children with and without low trauma fractures. Osteoporos Int 24:2015–2024PubMedCrossRef
71.
Binkley T, Johnson J, Vogel L, Kecskemethy H, Henderson R, Specker B (2005) Bone measurements by peripheral quantitative computed tomography (pQCT) in children with cerebral palsy. J Pediatr 147:791–796PubMedCrossRef
72.
Hogler W, Shaw N (2010) Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence. Clin Endocrinol (Oxf) 72:281–289CrossRef
73.
Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, Kanis JA (2011) International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 49:1271–1274PubMedCrossRef
74.
Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, Hogler W (2007) Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 92:443–449PubMedCrossRef
75.
Bayer M (2014) Reference values of osteocalcin and procollagen type I N-propeptide plasma levels in a healthy Central European population aged 0–18 years. Osteoporos Int 25:729–736PubMedCrossRef
76.
Morovat A, Catchpole A, Meurisse A, Carlisi A, Bekaert AC, Rousselle O, Paddon M, James T, Cavalier E (2013) IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children. Clin Chem Lab Med 51:2009–2018PubMedCrossRef
77.
Huang Y, Eapen E, Steele S, Grey V (2011) Establishment of reference intervals for bone markers in children and adolescents. Clin Biochem 44:771–778PubMedCrossRef
78.
Biver E (2012) Use of bone turnover markers in clinical practice. Curr Opin Endocrinol Diabetes Obes 19:468–473PubMedCrossRef
79.
McCloskey EV, Vasikaran S, Cooper C (2011) Official Positions for FRAX(R) clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). J Clin Densitom 14:220–222PubMedCrossRef
80.
Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056PubMedCrossRef
81.
Seibel MJ, Naganathan V, Barton I, Grauer A (2004) Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 19:323–329PubMedCrossRef
82.
Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH (2006) Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39:237–243PubMedCrossRef
83.
Eastell R, Hannon RA, Garnero P, Campbell MJ, Delmas PD (2007) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 22:1656–1660PubMedCrossRef
84.
Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH (2003) Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88:986–992PubMedCrossRef
85.
Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293–1299PubMedPubMedCentralCrossRef
86.
Ward LM, Rauch F, Matzinger MA, Benchimol EI, Boland M, Mack DR (2010) Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease. Osteoporos Int 21:331–337PubMedCrossRef
87.
Hartikka H, Makitie O, Mannikko M, Doria AS, Daneman A, Cole WG, Ala-Kokko L, Sochett EB (2005) Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 20:783–789PubMedCrossRef
88.
Fahiminiya S, Majewski J, Roughley P, Roschger P, Klaushofer K, Rauch F (2013) Whole-exome sequencing reveals a heterozygous LRP5 mutation in a 6-year-old boy with vertebral compression fractures and low trabecular bone density. Bone 57:41–46PubMedCrossRef
89.
Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Millan JL, Skrinar AM, Crine P, Landy H (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. New Eng J Med 366:904–913PubMedCrossRef
90.
Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tato L (2006) Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 149:174–179PubMedCrossRef
91.
Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427–1431PubMedCrossRef
92.
Ward LM, Glorieux FH, Rauch F, Verbruggen N, Heyden N, Lombardi A (2005) A randomized, placebo-controlled trial of oral alendronate in children and adolescents with osteogenesis imperfecta. Bone 36
93.
Rauch F, Munns CF, Land C, Cheung M, Glorieux FH (2009) Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 24:1282–1289PubMedCrossRef
94.
Kroger H, Vainio P, Nieminen J, Kotaniemi A (1995) Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology. Bone 17:157–159PubMedCrossRef
95.
Carter DR, Bouxsein ML, Marcus R (1992) New approaches for interpreting projected bone densitometry data. J Bone Miner Res 7:137–145PubMedCrossRef
96.
Rauch F, Plotkin H, DiMeglio L, Engelbert RH, Henderson RC, Munns C, Wenkert D, Zeitler P (2008) Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions. J Clin Densitom 11:22–28PubMedCrossRef
97.
98.
99.
Palomo T, Al-Jallad H, Moffatt P, Glorieux FH, Lentle B, Roschger P, Klaushofer K, Rauch F (2014) Skeletal characteristics associated with homozygous and heterozygous WNT1 mutations. Bone 67:63–70PubMedCrossRef
100.
101.
102.
Golden NH, Abrams SA (2014) Optimizing bone health in children and adolescents. Pediatrics 134:e1229–e1243PubMedCrossRef
103.
Abrams SA, Coss-Bu JA, Tiosano D (2013) Vitamin D: effects on childhood health and disease. Nat Rev Endocrinol 9:162–170PubMedCrossRef
104.
Julian-Almarcegui C, Gomez-Cabello A, Huybrechts I, Gonzalez-Aguero A, Kaufman JM, Casajus JA, Vicente-Rodriguez G (2015) Combined effects of interaction between physical activity and nutrition on bone health in children and adolescents: a systematic review. Nutr Rev 73:127–139PubMedCrossRef
105.
Handel MN, Heitmann BL, Abrahamsen B (2015) Nutrient and food intakes in early life and risk of childhood fractures: a systematic review and meta-analysis. Am J Clin Nutr 102:1182–1195PubMedCrossRef
106.
Tan VP, Macdonald HM, Kim S, Nettlefold L, Gabel L, Ashe MC, McKay HA (2014) Influence of physical activity on bone strength in children and adolescents: a systematic review and narrative synthesis. J Bone Miner Res 29:2161–2181PubMedCrossRef
107.
Institute of Medicine (2011) Dietary reference intakes for calcium and vitamin D. The National Academies Press, Washington
108.
Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M (2008) Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 122:398–417PubMedCrossRef
109.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930PubMedCrossRef
110.
Winzenberg T, Powell S, Shaw KA, Jones G (2011) Effects of vitamin D supplementation on bone density in healthy children: systematic review and meta-analysis. BMJ 342:c7254PubMedPubMedCentralCrossRef
111.
Edouard T, Glorieux FH, Rauch F (2011) Predictors and correlates of vitamin D status in children and adolescents with osteogenesis imperfecta. J Clin Endocrinol Metab 96:3193–3198PubMedCrossRef
112.
Benchimol EI, Ward LM, Gallagher JC, Rauch F, Barrowman N, Warren J, Beedle S, Mack DR (2007) Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 45:538–545PubMedCrossRef
113.
Kaste SC, Qi A, Smith K, Surprise H, Lovorn E, Boyett J, Ferry RJ Jr, Relling MV, Shurtleff SA, Pui CH, Carbone L, Hudson MM, Ness KK (2014) Calcium and cholecalciferol supplementation provides no added benefit to nutritional counseling to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 61:885–893PubMedPubMedCentralCrossRef
114.
Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP (2014) Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 348:g2035PubMedPubMedCentralCrossRef
115.
Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691PubMedPubMedCentralCrossRef
116.
Winzenberg T, Shaw K, Fryer J, Jones G (2006) Effects of calcium supplementation on bone density in healthy children: meta-analysis of randomised controlled trials. BMJ 333:775PubMedPubMedCentralCrossRef
117.
Behringer M, Gruetzner S, McCourt M, Mester J (2014) Effects of weight-bearing activities on bone mineral content and density in children and adolescents: a meta-analysis. J Bone Miner Res 29:467–478PubMedCrossRef
118.
Dubnov-Raz G, Azar M, Reuveny R, Katz U, Weintraub M, Constantini NW (2015) Changes in fitness are associated with changes in body composition and bone health in children after cancer. Acta Paediatr 104:1055–1061PubMedCrossRef
119.
Hough JP, Boyd RN, Keating JL (2010) Systematic review of interventions for low bone mineral density in children with cerebral palsy. Pediatrics 125:e670–e678PubMedCrossRef
120.
Mandel K, Atkinson S, Barr RD, Pencharz P (2004) Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 22:1215–1221PubMedCrossRef
121.
Kalayci AG, Kansu A, Girgin N, Kucuk O, Aras G (2001) Bone mineral density and importance of a gluten-free diet in patients with celiac disease in childhood. Pediatrics 108:E89PubMedCrossRef
122.
Avgeri M, Papadopoulou A, Platokouki H, Douros K, Rammos S, Nicolaidou P, Aronis S (2008) Assessment of bone mineral density and markers of bone turnover in children under long-term oral anticoagulant therapy. J Pediatr Hematol Oncol 30:592–597PubMedCrossRef
123.
Modesto W, Bahamondes MV, Bahamondes L (2015) Prevalence of low bone mass and osteoporosis in long-term users of the injectable contraceptive depot medroxyprogesterone acetate. J Womens Health (Larchmt) 24:636–640CrossRef
124.
Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1587–1609PubMedCrossRef
125.
Bodor M, McDonald CM (2013) Why short stature is beneficial in Duchenne muscular dystrophy. Muscle Nerve 48:336–342PubMedCrossRef
126.
Dubner SE, Shults J, Baldassano RN, Zemel BS, Thayu M, Burnham JM, Herskovitz RM, Howard KM, Leonard MB (2009) Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn’s disease. Gastroenterology 136:123–130PubMedCrossRef
127.
Dwan K, Phillipi CA, Steiner RD, Basel D (2014) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 7:CD005088
128.
Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, Rauch F, Tugwell P, Moher D (2007) Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev: CD005324
129.
Ward LM, Rauch F (2013) Oral bisphosphonates for paediatric osteogenesis imperfecta? Lancet 282:1388–1389CrossRef
130.
Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. New Eng J Med 339:947–952PubMedCrossRef
131.
Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M (2012) Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 25:485–491PubMedCrossRef
132.
Grey A, Bolland M, Wattie D, Horne A, Gamble G, Reid IR (2010) Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. J Bone Miner Res 25:2251–2255PubMedCrossRef
133.
Ward LM, Denker AE, Porras A, Shugarts S, Kline W, Travers R, Mao C, Rauch F, Maes A, Larson P, Deutsch P, Glorieux FH (2005) Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 90:4051–4056PubMedCrossRef
134.
Golden NH, Iglesias EA, Jacobson MS, Carey D, Meyer W, Schebendach J, Hertz S, Shenker IR (2005) Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 90:3179–3185PubMedCrossRef
135.
Bishop N, Adami S, Ahmed SF, Anton J, Arundel P, Burren CP, Devogelaer JP, Hangartner T, Hosszu E, Lane JM, Lorenc R, Makitie O, Munns CF, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD (2013) Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 382:1424–1432PubMedCrossRef
136.
Bianchi ML, Colombo C, Assael BM, Dubini A, Lombardo M, Quattrucci S, Bella S, Collura M, Messore B, Raia V, Poli F, Bini R, Albanese CV, De Rose V, Costantini D, Romano G, Pustorino E, Magazzu G, Bertasi S, Lucidi V, Traverso G, Coruzzo A, Grzejdziak AD (2013) Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. Lancet Respir Med 1:377–385PubMedCrossRef
137.
Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T (2005) Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 44:813–818CrossRef
138.
Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, Viapiana O, Adami S (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20:758–763PubMedCrossRef
139.
Ward LM, Rauch F, Whyte MP, D’Astous J, Gates PE, Grogan D, Lester EL, McCall RE, Pressly TA, Sanders JO, Smith PA, Steiner RD, Sullivan E, Tyerman G, Smith-Wright DL, Verbruggen N, Heyden N, Lombardi A, Glorieux FH (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 96:355–364PubMedCrossRef
140.
Munns CF, Rauch F, Travers R, Glorieux FH (2005) Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 20:1235–1243PubMedCrossRef
141.
Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH (2006) Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 39:901–906PubMedCrossRef
142.
Astrom E, Jorulf H, Soderhall S (2007) Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child 92:332–338PubMedCrossRef
143.
Rauch F, Munns C, Land C, Glorieux FH (2006) Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 91:1268–1274PubMedCrossRef
144.
Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH (2006) Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 148:456–460PubMedCrossRef
145.
Zeitlin L, Rauch F, Plotkin H, Glorieux FH (2003) Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111:1030–1036PubMedCrossRef
146.
Vuorimies I, Toiviainen-Salo S, Hero M, Makitie O (2011) Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr 75:346–353PubMedCrossRef
147.
Ooi HL, Briody J, Biggin A, Cowell CT, Munns CF (2013) Intravenous zoledronic acid given every 6 months in childhood osteoporosis. Horm Res Paediatr 80:179–184PubMedCrossRef
148.
Gandrud LM, Cheung JC, Daniels MW, Bachrach LK (2003) Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metab 16:887–892PubMedCrossRef
149.
Steelman J, Zeitler P (2003) Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 142:417–423PubMedCrossRef
150.
Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteopetrosis. New Eng J Med 349:457–463PubMedCrossRef
151.
Rauch F, Cornibert S, Cheung M, Glorieux FH (2007) Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40:821–827PubMedCrossRef
152.
Biggin A, Briody JN, Ormshaw E, Wong KK, Bennetts BH, Munns CF (2014) Fracture during intravenous bisphosphonate treatment in a child with osteogenesis imperfecta: an argument for a more frequent, low-dose treatment regimen. Horm Res Paediatr 81:204–210PubMedCrossRef
153.
Biggin A, Zheng L, Briody JN, Coorey CP, Munns CF (2015) The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta. Horm Res Paediatr 83:183–189PubMedCrossRef
154.
Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, Goltzman D, Hanley DA, Hodsman A, Josse R, Jovaisas A, Juby A, Kaiser S, Karaplis A, Kendler D, Khan A, Ngui D, Olszynski W, Ste-Marie LG, Adachi J (2014) Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician 60:324–333PubMedPubMedCentral
155.
Unal E, Abaci A, Bober E, Buyukgebiz A (2006) Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab 19:523–528PubMed
156.
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491PubMedCrossRef
157.
Malmgren B, Astrom E, Soderhall S (2008) No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 37:196–200PubMedCrossRef
158.
Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F (2008) Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 153:719–720PubMedCrossRef
159.
Brown JJ, Ramalingam L, Zacharin MR (2008) Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Clin Endocrinol (Oxf) 68:863–867CrossRef
160.
Bhatt RN, Hibbert SA, Munns CF (2014) The use of bisphosphonates in children: review of the literature and guidelines for dental management. Aust Dent J 59:9–19PubMedCrossRef
161.
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23PubMedCrossRef
162.
Hegazy A, Kenawey M, Sochett E, Tile L, Cheung AM, Howard AW (2015) Unusual femur stress fractures in children with osteogenesis imperfecta and intramedullary rods on long-term intravenous pamidronate therapy. J Pediatr Orthop Epub ahead of print: 2015 Jun 8 doi:10.​1097/​BPO.​0000000000000552​
163.
Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19:1779–1786PubMedCrossRef
164.
Anam EA, Rauch F, Glorieux FH, Fassier F, Hamdy R (2015) Osteotomy healing in children with osteogenesis imperfecta receiving bisphosphonate treatment. J Bone Miner Res 30:1362–1368PubMedCrossRef
165.
Papapoulos SE, Cremers SC (2007) Prolonged bisphosphonate release after treatment in children. New Eng J Med 356:1075–1076PubMedCrossRef
166.
Djokanovic N, Klieger-Grossmann C, Koren G (2008) Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 30:1146–1148PubMedCrossRef
167.
Green SB, Pappas AL (2014) Effects of maternal bisphosphonate use on fetal and neonatal outcomes. Am J Health Syst Pharm 71:2029–2036PubMedCrossRef
168.
Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, Moretti M, Koren G, Ito S (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44:428–430PubMedCrossRef
169.
Munns CF, Rauch F, Ward L, Glorieux FH (2004) Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19:1742–1745PubMedCrossRef
170.
Faje AT, Fazeli PK, Miller KK, Katzman DK, Ebrahimi S, Lee H, Mendes N, Snelgrove D, Meenaghan E, Misra M, Klibanski A (2014) Fracture risk and areal bone mineral density in adolescent females with anorexia nervosa. Int J Eat Disord 47:458–466PubMedPubMedCentralCrossRef
171.
Divasta AD, Feldman HA, Gordon CM (2014) Vertebral fracture assessment in adolescents and young women with anorexia nervosa: a case series. J Clin Densitom 17:207–211PubMedCrossRef
172.
173.
Nattiv A, Loucks AB, Manore MM, Sanborn CF, Sundgot-Borgen J, Warren MP (2007) American College of Sports Medicine position stand. The female athlete triad. Med Sci Sports Exerc 39:1867–1882PubMedCrossRef
174.
Saraff V, Hoegler W (2015) Endocrinology and adolescence: osteoporosis in children: diagnosis and management. Eur J Endocrinol 173(6):R185–R1897PubMedCrossRef
175.
Korula S, Titmuss AT, Biggin A, Munns CF (2015) A practical approach to children with recurrent fractures. Endocr Dev 28:210–225PubMedCrossRef
176.
Kim MJ, Kim SN, Lee IS, Chung S, Lee J, Yang Y, Lee I, Koh SE (2015) Effects of bisphosphonates to treat osteoporosis in children with cerebral palsy: a meta-analysis. J Pediatr Endocrinol Metab 28(11–12):1343–1350PubMed
177.
Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221–1230PubMedPubMedCentralCrossRef
178.
Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK (2009) Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182–195PubMedCrossRef
179.
Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schuler C, Stolina M, Kostenuik PJ, Erben RG (2009) Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 60:1427–1437PubMedCrossRef
180.
Dempster DW, Lambing CL, Kostenuik PJ, Grauer A (2012) Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther 34:521–536PubMedCrossRef
181.
Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E (2012) First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 12:183–188PubMed
182.
Karras NA, Polgreen LE, Ogilvie C, Manivel JC, Skubitz KM, Lipsitz E (2013) Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl. J Clin Oncol 31:e200–e202PubMedPubMedCentralCrossRef
183.
Lange T, Stehling C, Frohlich B, Klingenhofer M, Kunkel P, Schneppenheim R, Escherich G, Gosheger G, Hardes J, Jurgens H, Schulte TL (2013) Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J 22:1417–1422PubMedPubMedCentralCrossRef
184.
Boyce AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE, Bassim C, Cherman N, Ellsworth M, Kasa-Vubu JZ, Farley FA, Molinolo AA, Bhattacharyya N, Collins MT (2012) Denosumab treatment for fibrous dysplasia. J Bone Miner Res 27:1462–1470PubMedPubMedCentralCrossRef
185.
Wang HD, Boyce AM, Tsai JY, Gafni RI, Farley FA, Kasa-Vubu JZ, Molinolo AA, Collins MT (2014) Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab 99:891–897PubMedPubMedCentralCrossRef
186.
Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, Jang G (2014) Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol 54:168–178PubMedCrossRef
187.
Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26PubMedCrossRef
188.
189.
Weintraub JA, Breland CE (2015) Challenges, benefits, and factors to enhance recruitment and inclusion of children in pediatric dental research. Int J Paediatr Dent 25:310–316PubMedPubMedCentralCrossRef
190.
Makitie O, Doria AS, Henriques F, Cole WG, Compeyrot S, Silverman E, Laxer R, Daneman A, Sochett EB (2005) Radiographic vertebral morphology: a diagnostic tool in pediatric osteoporosis. J Pediatr 146:395–401PubMedCrossRef
191.
Fung EB, Harmatz PR, Milet M, Coates, T, Thompson, AA, Ranalli, M, Mignaca, R Scher, C Giardina, P Robertson, S, Neumayr, L, Vichinsky, E, The Multi-Center Iron Overload Study Group (2008) Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 43:162–168
192.
Dosa NP, Eckrich M, Katz DA, Turk M, Liptak GS (2007) Incidence, prevalence, and characteristics of fractures in children, adolescents, and adults with spina bifida. J Spinal Cord Med 30 Suppl 1:S5–9
193.
Nakhla M, Scuccimarri R, Duffy KN, Chedeville G, Campillo S, Duffy CM, Azouz EM, Shenouda N, Sharma AK, Rodd C (2009) Prevalence of Vertebral Fractures in Children with Chronic Rheumatic Diseases at Risk for Osteopenia. J Pediatr 154:438–443
194.
Engkakul P, Mahachoklertwattana P, Jaovisidha S, Chuansumrit A, Poomthavorn P, Chitrapazt N, Chuncharunee S (2013) Unrecognized vertebral fractures in adolescents and young adults with thalassemia syndromes. J Pediatr Hematol Oncol 35:212–217
195.
Mayranpaa MK, Viljakainen HT, Toiviainen-Salo S, Kallio PE, Makitie O (2012) Impaired bone health and asymptomatic vertebral compressions in fracture-prone children: a case-control study. J Bone Miner Res 27:1413–1424
196.
Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA (2005) Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 25:786–791
Metadata
Title
The management of osteoporosis in children
Authors
L. M. Ward
V. N. Konji
J. Ma
Publication date
01-07-2016
Publisher
Springer London
Published in
Osteoporosis International / Issue 7/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3515-9

Other articles of this Issue 7/2016

Osteoporosis International 7/2016 Go to the issue

Letter

Intensity is a subjective construct

Original Article

Vitamin E homologues α- and γ-tocopherol are not associated with bone turnover markers or bone mineral density in peri-menopausal and post-menopausal women

Erratum

Erratum to: Medication therapy for attention deficit/hyperactivity disorder is associated with lower risk of fracture: a retrospective cohort study

Original Article

Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study

Original Article

Has Choosing Wisely® affected rates of dual-energy X-ray absorptiometry use?

Case Report

Hypercalcemia after discontinuation of long-term denosumab treatment